Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
Financing Led by Bain Capital Life Sciences - Andrew Hack, M.D., Ph.D., a Managing Director of Bain Capital Life Sciences, to Join Nuvalent Board of Directors
Funding to Advance Parallel Lead Programs in ROS1-positive and ALK-positive NSCLC to Phase 1/2... Biopharmaceuticals, Oncology, Venture Capital Nuvalent, NSCLC
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Funding | Non-Small Cell Lung Cancer | Pharmaceuticals | Venture Capital